A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Article ID	Journal	Published Year	Pages	File Type
6072755	Journal of the American Academy of Dermatology	2014	7 Pages	PDF

Abstract

A high proportion of patients responded to ixekizumab therapy and maintained clinicalÂ responses over 1 year of treatment with no unexpected safety signals.

Keywords

sPGA OLE RCT Open-label extension NRI SAE PASI75 static Physician Global Assessment interleukin 17 Ixekizumab open label PASI Long-term adverse event Serious adverse event psoriasis area and severity index Monoclonal antibodies Psoriasis

Related Topics

Health Sciences Medicine and Dentistry Dermatology

Preview

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Authors

Kenneth B. MD, Craig L. MD, Mark MD, Andrew MD, MBA, Gregory S. PhD, Daniel MD, PhD, Janelle PhD, Michael MD,